Dr. Albert DeNittis, MD
Claim this profileLankenau Medical Center
Expert in Lung Cancer
Expert in Breast Cancer
59 reported clinical trials
120 drugs studied
About Albert DeNittis, MD
Education:
- Received MD from Sidney Kimmel Medical College (formerly Jefferson Medical College) in 1986.
- Completed Residency in Internal Medicine at Lankenau Medical Center in 1989.
- Finished Fellowship in Hematology/Oncology at Fox Chase Cancer Center in 1992.
Experience:
- Affiliated with Lankenau Medical Center and Main Line Health.
- Practices as a hematologist and oncologist.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Albert DeNittis, MD is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
More about Albert DeNittis, MD
Clinical Trial Related5 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Albert DeNittis, MD has experience with
- Paclitaxel
- Carboplatin
- Pembrolizumab
- Atezolizumab
- Olaparib
- Docetaxel
Breakdown of trials Albert DeNittis, MD has run
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Albert DeNittis, MD specialize in?
Albert DeNittis, MD focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Albert DeNittis, MD currently recruiting for clinical trials?
Yes, Albert DeNittis, MD is currently recruiting for 18 clinical trials in Wynnewood Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Albert DeNittis, MD has studied deeply?
Yes, Albert DeNittis, MD has studied treatments such as Paclitaxel, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Albert DeNittis, MD?
Apply for one of the trials that Albert DeNittis, MD is conducting.
What is the office address of Albert DeNittis, MD?
The office of Albert DeNittis, MD is located at: Lankenau Medical Center, Wynnewood, Pennsylvania 19096 United States. This is the address for their practice at the Lankenau Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.